Tumor stasis in the treated animals was observed in this xenograft model as well, showing that a clinically relevant dose of fulvestrant adequately opposed the stimulatory effects of estrogen in this model with a modest but significant downregulation of ER expression (Fig. 4). This evidence concerns the gene ESR1 and neoplasm.